US Patent

US9486530 — Ganciclovir compositions and related methods

Formulation · Assigned to Exela Pharma Sciences LLC · Expires 2034-09-02 · 8y remaining

Vulnerability score 42/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects ready-to-use, substantially particulate-free, and stable ganciclovir formulations and methods for their manufacture and administration.

USPTO Abstract

Gancyclovir formulations that are ready-to-use, substantially particulate free, and stable upon storage are disclosed. Methods of manufacture and administration of such compositions are also provided.

Drugs covered by this patent

Patent Metadata

Patent number
US9486530
Jurisdiction
US
Classification
Formulation
Expires
2034-09-02
Drug substance claim
No
Drug product claim
Yes
Assignee
Exela Pharma Sciences LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.